ECSP21015267A - Compuestos de 2,6-diaminopiridina - Google Patents
Compuestos de 2,6-diaminopiridinaInfo
- Publication number
- ECSP21015267A ECSP21015267A ECSENADI202115267A ECDI202115267A ECSP21015267A EC SP21015267 A ECSP21015267 A EC SP21015267A EC SENADI202115267 A ECSENADI202115267 A EC SENADI202115267A EC DI202115267 A ECDI202115267 A EC DI202115267A EC SP21015267 A ECSP21015267 A EC SP21015267A
- Authority
- EC
- Ecuador
- Prior art keywords
- formula
- compounds
- diaminopyridine compounds
- diaminopyridine
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un compuesto de Fórmula I (VER ANEXO) o una sal farmacéuticamente aceptable de este, y el uso de los compuestos de Fórmula I para el tratamiento de afecciones metabólicas, tales como la diabetes mellitus tipo 2, la insuficiencia cardíaca, la enfermedad renal diabética y la esteatohepatitis no alcohólica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726520P | 2018-09-04 | 2018-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21015267A true ECSP21015267A (es) | 2021-04-29 |
Family
ID=67982138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202115267A ECSP21015267A (es) | 2018-09-04 | 2021-03-03 | Compuestos de 2,6-diaminopiridina |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10781212B2 (es) |
| EP (1) | EP3846809B1 (es) |
| JP (1) | JP6813720B1 (es) |
| KR (1) | KR102365535B1 (es) |
| CN (1) | CN112601525B (es) |
| AR (1) | AR117640A1 (es) |
| AU (1) | AU2019334877B2 (es) |
| BR (1) | BR112021001881A2 (es) |
| CA (1) | CA3111725C (es) |
| CL (1) | CL2021000528A1 (es) |
| CO (1) | CO2021002768A2 (es) |
| CR (1) | CR20210085A (es) |
| DO (1) | DOP2021000027A (es) |
| EA (1) | EA202190302A1 (es) |
| EC (1) | ECSP21015267A (es) |
| ES (1) | ES2971802T3 (es) |
| IL (1) | IL280598B2 (es) |
| JO (1) | JOP20210039B1 (es) |
| MA (1) | MA53547A (es) |
| MX (1) | MX2021002472A (es) |
| MY (1) | MY200531A (es) |
| PE (1) | PE20211595A1 (es) |
| PH (1) | PH12021550449A1 (es) |
| SG (1) | SG11202101687TA (es) |
| TW (1) | TWI714231B (es) |
| UA (1) | UA124917C2 (es) |
| WO (1) | WO2020051058A1 (es) |
| ZA (1) | ZA202100700B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161621B2 (en) | 2018-07-16 | 2024-12-10 | The Regents Of The University Of Colorado | Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease |
| TWI750685B (zh) * | 2019-06-17 | 2021-12-21 | 美商美國禮來大藥廠 | 二取代吡唑化合物 |
| CN114846009B (zh) | 2019-12-24 | 2023-12-12 | 杭州中美华东制药有限公司 | 具有khk抑制作用的化合物 |
| CN111423420A (zh) * | 2020-04-30 | 2020-07-17 | 广州博济医药生物技术股份有限公司 | 作为己酮糖激酶抑制剂的并环化合物 |
| JP2024501507A (ja) * | 2020-12-25 | 2024-01-12 | スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド | ケトヘキソキナーゼ阻害剤及びその用途 |
| EP4681774A3 (en) | 2021-03-29 | 2026-03-25 | Gilead Sciences, Inc. | Khk inhibitors |
| WO2023146785A1 (en) * | 2022-01-26 | 2023-08-03 | Eli Lilly And Company | Pyrrolidine compounds |
| CN118679155A (zh) * | 2022-02-09 | 2024-09-20 | 上海研健新药研发有限公司 | 一种khk抑制剂，其制备方法和应用 |
| JP2025539698A (ja) * | 2022-12-08 | 2025-12-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規シアノピリジンｋｈｋ阻害剤化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20100516T1 (hr) * | 2006-09-20 | 2010-10-31 | Eli Lilly And Company | Tiazolpirazolopirimidini kao antagonisti receptora crf1 |
| AR099937A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| MA40434B1 (fr) * | 2014-05-15 | 2019-09-30 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka |
| SI3397631T1 (sl) | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
-
2019
- 2019-08-23 TW TW108130153A patent/TWI714231B/zh active
- 2019-08-27 AR ARP190102434A patent/AR117640A1/es not_active Application Discontinuation
- 2019-08-29 IL IL280598A patent/IL280598B2/en unknown
- 2019-08-29 MX MX2021002472A patent/MX2021002472A/es unknown
- 2019-08-29 EP EP19769621.4A patent/EP3846809B1/en active Active
- 2019-08-29 CR CR20210085A patent/CR20210085A/es unknown
- 2019-08-29 UA UAA202100674A patent/UA124917C2/uk unknown
- 2019-08-29 MA MA053547A patent/MA53547A/fr unknown
- 2019-08-29 MY MYPI2021001044A patent/MY200531A/en unknown
- 2019-08-29 CA CA3111725A patent/CA3111725C/en active Active
- 2019-08-29 WO PCT/US2019/048788 patent/WO2020051058A1/en not_active Ceased
- 2019-08-29 EA EA202190302A patent/EA202190302A1/ru unknown
- 2019-08-29 SG SG11202101687TA patent/SG11202101687TA/en unknown
- 2019-08-29 BR BR112021001881-6A patent/BR112021001881A2/pt unknown
- 2019-08-29 PE PE2021000355A patent/PE20211595A1/es unknown
- 2019-08-29 ES ES19769621T patent/ES2971802T3/es active Active
- 2019-08-29 KR KR1020217006473A patent/KR102365535B1/ko active Active
- 2019-08-29 JP JP2020537626A patent/JP6813720B1/ja active Active
- 2019-08-29 CN CN201980057907.2A patent/CN112601525B/zh active Active
- 2019-08-29 US US16/555,075 patent/US10781212B2/en active Active
- 2019-08-29 AU AU2019334877A patent/AU2019334877B2/en active Active
-
2021
- 2021-02-01 ZA ZA2021/00700A patent/ZA202100700B/en unknown
- 2021-02-16 DO DO2021000027A patent/DOP2021000027A/es unknown
- 2021-03-01 CO CONC2021/0002768A patent/CO2021002768A2/es unknown
- 2021-03-02 PH PH12021550449A patent/PH12021550449A1/en unknown
- 2021-03-03 CL CL2021000528A patent/CL2021000528A1/es unknown
- 2021-03-03 EC ECSENADI202115267A patent/ECSP21015267A/es unknown
- 2021-03-04 JO JOJO/P/2021/0039A patent/JOP20210039B1/ar active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21015267A (es) | Compuestos de 2,6-diaminopiridina | |
| CL2021003342A1 (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa. | |
| CL2022003395A1 (es) | Antagonistas del receptor de lpa y usos de los mismos | |
| DOP2021000273A (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| CL2013001558A1 (es) | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. | |
| MX388748B (es) | Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. | |
| EA201990518A1 (ru) | Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1 | |
| BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
| MX382748B (es) | Compuestos heterociclicos utiles para el tratamiento de una enfermedad. | |
| AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| CR20120062A (es) | Terapia combinada para el tratamiento de la diabetes | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| AR079050A1 (es) | Compuestos benzoimidazolicos y sus usos | |
| MX2021008263A (es) | Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. | |
| MX389091B (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2. | |
| MX2019010108A (es) | Derivados de azetidina. | |
| CL2025001515A1 (es) | Uso de finerenona para tratar la enfermedad renal crónica en la diabetes mellitus tipo i. | |
| AR100420A1 (es) | Derivados bicíclicos y composición farmacéutica que los incluye | |
| AR109895A1 (es) | Compuestos cíclicos de péptido tirosina tirosina como moduladores de neuropéptido y receptores | |
| AR119173A1 (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| EA202192957A1 (ru) | Дизамещенные пиразольные соединения в качестве ингибиторов кетогексокиназы | |
| AR115865A2 (es) | Compuestos terapéuticos |